Progyny Inc is a benefits management company that specializes in providing fertility and family-building benefits to employers and their employees
The company aims to improve the employee experience through comprehensive fertility solutions, including in vitro fertilization (IVF), egg freezing, and adoption services. Progyny partners with a network of fertility specialists to offer personalized care and support, helping individuals and couples navigate their family-building journeys. By focusing on innovative health services and a tailored approach, Progyny enhances the overall health and well-being of families while also addressing the financial implications of fertility treatments for employers.
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at UnitedHealth (NYSEUNH) and its peers.
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the health insurance providers stocks, including Progyny (NASDAQPGNY) and its peers.
NASDAQ:PGNY is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced.
Fertility benefits company Progyny (NASDAQPGNY) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 10.6% year on year to $298.4 million. On top of that, next quarter’s revenue guidance ($309 million at the midpoint) was surprisingly good and 10.3% above what analysts were expecting. Its non-GAAP profit of $0.42 per share was 13.5% above analysts’ consensus estimates.
The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Reports Quarterly Revenue of $298.4 Million, Reflecting 10.6% GrowthGenerated $52.2 Million of Quarterly Operating Cash FlowIssues Financial Guidance for 2025, Reflecting Tenth Consecutive Year of Revenue Growth
NEW YORK, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women’s health benefits solution, will report its financial results for the quarterly period and full year ended December 31, 2024, after the close of the market on Thursday, February 27, 2025.
NEW YORK, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building and women’s health benefits solution, today announced the appointment of 30-year healthcare industry veteran Debra Morris to its board of directors, effective January 16, 2025.
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Progyny, Inc. (“Progyny” or the “Company”) (NASDAQPGNY) investors concerning the Company’s possible violations of the federal securities laws.
Law Offices of Howard G. Smith announces an investigation on behalf of Progyny, Inc. (“Progyny” or the “Company”) (NASDAQPGNY) investors concerning the Company’s possible violations of federal securities laws.
SAN DIEGO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP is investigating Progyny, Inc. (NASDAQPGNY) to determine whether certain Progyny officers and directors violated securities laws and breached fiduciary duties to shareholders. Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States.
